JP2023531872A - 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法 - Google Patents

急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法 Download PDF

Info

Publication number
JP2023531872A
JP2023531872A JP2022573664A JP2022573664A JP2023531872A JP 2023531872 A JP2023531872 A JP 2023531872A JP 2022573664 A JP2022573664 A JP 2022573664A JP 2022573664 A JP2022573664 A JP 2022573664A JP 2023531872 A JP2023531872 A JP 2023531872A
Authority
JP
Japan
Prior art keywords
amino acids
free amino
pharmaceutical formulation
present
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531872A5 (https=
Inventor
ヴィディヤサガル，サダシヴァン
グロッシェ，アストリッド
シュー，シャオドン
アンゴリ，ダミアーノ
ガット，スティーブン，ジェー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amilyfe LLC
Original Assignee
Amilyfe LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amilyfe LLC filed Critical Amilyfe LLC
Publication of JP2023531872A publication Critical patent/JP2023531872A/ja
Publication of JP2023531872A5 publication Critical patent/JP2023531872A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022573664A 2020-05-29 2021-05-28 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法 Pending JP2023531872A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063032185P 2020-05-29 2020-05-29
US63/032,185 2020-05-29
US202063080470P 2020-09-18 2020-09-18
US63/080,470 2020-09-18
US202063088813P 2020-10-07 2020-10-07
US63/088,813 2020-10-07
US202163136404P 2021-01-12 2021-01-12
US63/136,404 2021-01-12
PCT/US2021/034807 WO2021243183A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Publications (2)

Publication Number Publication Date
JP2023531872A true JP2023531872A (ja) 2023-07-26
JP2023531872A5 JP2023531872A5 (https=) 2024-08-09

Family

ID=78722883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573664A Pending JP2023531872A (ja) 2020-05-29 2021-05-28 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法

Country Status (10)

Country Link
US (1) US20230201151A1 (https=)
EP (1) EP4157218A4 (https=)
JP (1) JP2023531872A (https=)
KR (1) KR20230018474A (https=)
CN (1) CN115697301A (https=)
AU (1) AU2021280328A1 (https=)
BR (1) BR112022024033A2 (https=)
CA (1) CA3177780A1 (https=)
MX (1) MX2022015044A (https=)
WO (1) WO2021243183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036277B (zh) * 2022-07-19 2023-10-31 广州国家实验室 氯离子在预防、治疗冠状病毒所致疾病中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003162A1 (en) * 2001-06-19 2003-01-02 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
WO2020092639A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3691628A1 (en) * 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
WO2019070759A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003162A1 (en) * 2001-06-19 2003-01-02 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
WO2020092639A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. AGRIC. FOOD CHEM., vol. 55, JPN6025018240, 2007, pages 1188 - 1192, ISSN: 0005748849 *
MYCOBIOLOGY, vol. Vol.35,Issue4, JPN6025018241, 2007, pages 215 - 218, ISSN: 0005748850 *

Also Published As

Publication number Publication date
KR20230018474A (ko) 2023-02-07
BR112022024033A2 (pt) 2022-12-20
US20230201151A1 (en) 2023-06-29
WO2021243183A8 (en) 2022-01-13
WO2021243183A1 (en) 2021-12-02
MX2022015044A (es) 2023-01-04
AU2021280328A1 (en) 2022-11-17
CN115697301A (zh) 2023-02-03
EP4157218A4 (en) 2024-06-26
EP4157218A1 (en) 2023-04-05
CA3177780A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US9913819B2 (en) Methods of treating or preventing fibrotic lung diseases
CA3182274A1 (en) Inhaled statins for treatment of viral respiratory diseases
CA3075271C (en) Methods of using dipivefrin
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
JP7359519B2 (ja) ライノウイルス感染症の予防又は治療のための薬物
JP2023520323A (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
JP2023531872A (ja) 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
JP2024153711A (ja) 急性増悪をポリクローナル免疫グロブリンで予防または治療するための方法および組成物
US20230233514A1 (en) Antiviral compounds and methods of using the same
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
JP2023524693A (ja) ラクトフェリンの投与によるＳＡＲＳ－ＣｏＶ－２ウイルス侵入の阻害およびその使用
EP1437134A1 (en) Anti-influenza drugs
CN115443126A (zh) 用于预防或治疗SARS-CoV-2感染的相容性溶质
WO2021252378A1 (en) Prevention or treatment of covid-19
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
CN108926707B (zh) Pf4的抗rsv应用
JP2015534943A (ja) Ｃｂｐ／カテニン阻害剤を用いるウイルス性及び感染性疾病の治療
EP4135685A1 (en) Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus
JP2003155230A (ja) 抗インフルエンザ薬
US20220016160A1 (en) Method for preventing or treating infection of respiratory virus utilizing gold nanoparticles
WO2022146399A1 (en) Dual inhibition of sars-cov-2 virus of leukotriene ltd4 receptor antagonist montelukast
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209